EQS-News: Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division
|
EQS-News: Marinomed Biotech AG
/ Key word(s): Strategic Company Decision/AGM/EGM
Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division
Korneuburg, Austria, 19. December 2024 – Marinomed Biotech AG (VSE:MARI) announces that the majority of shareholders approved the sale of the Carragelose business unit to the French company Unither Pharmaceuticals at today's extraordinary general meeting. This approval is an important prerequisite for the closing of the transaction. In November 2024, Marinomed signed an agreement on the sale of the Carragelose business, which provides for upfront and milestone payments of in total up to EUR 20 million. Closing of the deal is still subject to other conditions such as approval in accordance with the Investment Control Act. Furthermore, Dr. Karl Mahler has been elected as member of the Supervisory Board. He holds a doctorate in economics and held several leadership positions in corporate planning and investor relations, including over 20 years as Head of Investor Relations at Hoffman La Roche. After the resignation of Dr. Eva Hofstädter-Thalmann and Dr. Ulrich Kinzel, the Supervisory Board now consists of four members, two women and two men. All other proposed resolutions of the Management Board and Supervisory Board, including the creation of new authorized and conditional capital, were also approved by large majorities. “The shareholders' approval of the sale of the Carragelose business is essential for the Company's continued existence. Our strategic focus is clearly on the commercialization of the Marinosolv products Budesolv and Tacrosolv and the expansion of the Solv4U service offering. We thank our shareholders for their support and are working hard to lead the Company to profitability,” says Andreas Grassauer, CEO of Marinomed. Further information on the extraordinary general meeting, including the voting results and the Management Board presentation can be found in the investors section of the corporate website at: https://www.marinomed.com/en/investors-esg/annual-general-meeting. About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of Carragelose®. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com. For further inquiries contact:
Disclaimer This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.
19.12.2024 CET/CEST This Corporate News was distributed by EQS Group. www.eqs.com |
| Language: | English |
| Company: | Marinomed Biotech AG |
| Hovengasse 25 | |
| 2100 Korneuburg | |
| Austria | |
| Phone: | +43 2262 90300 |
| E-mail: | office@marinomed.com |
| Internet: | www.marinomed.com |
| ISIN: | ATMARINOMED6 |
| WKN: | A2N9MM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market) |
| EQS News ID: | 2054983 |
| End of News | EQS News Service |
|
|
2054983 19.12.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 4,67 | 6,14 | 8,12 | 11,63 | 11,28 | 9,18 | 0,00 | |
| EBITDA1,2 | -4,90 | -5,88 | -5,39 | -3,54 | -4,24 | -4,45 | 0,00 | |
| EBITDA-Margin3 | -104,93 | -95,77 | -66,38 | -30,44 | -37,59 | -48,48 | 0,00 | |
| EBIT1,4 | -5,14 | -6,21 | -5,82 | -4,14 | -4,91 | -5,13 | 0,00 | |
| EBIT-Margin5 | -110,06 | -101,14 | -71,68 | -35,60 | -43,53 | -55,88 | 0,00 | |
| Net Profit (Loss)1 | -12,10 | -7,22 | -6,01 | -5,89 | -6,40 | -6,80 | 0,00 | |
| Net-Margin6 | -259,10 | -117,59 | -74,02 | -50,65 | -56,74 | -74,07 | 0,00 | |
| Cashflow1,7 | -4,32 | -7,64 | -6,89 | -4,87 | -5,20 | -4,53 | 0,00 | |
| Earnings per share8 | -12,10 | -5,10 | -4,10 | -4,00 | -4,30 | -4,50 | -2,40 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: BDO
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Marinomed Biotech | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A2N9MM | ATMARINOMED6 | AG | 25,43 Mio € | 01.02.2019 | Halten | 8FWR88QM+8R |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -7,15 | 0,00 | 0,00 | -3,15 | -2,51 | -5,62 | 2,77 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 20.06.2024 | 22.05.2024 | 20.08.2024 | 21.11.2024 | 16.04.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +45,10% | +19,90% | -52,17% | -53,57% | -80,93% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
